Guangzhou Innogen Pharmaceutical Group Co Ltd Class H (HK:2591)
:2591
Want to see HK:2591 full AI Analyst Report?
2591 Stock Chart & Stats
HK$30.42
--
Market closed
HK$30.42
--
Day’s Range― - ―
52-Week RangeHK$13.73 - HK$74.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)470.32K
Market Cap
HK$6.40B
Enterprise ValueHK$4.84B
Total Cash (Recent Filing)HK$1.21B
Total Debt (Recent Filing)HK$166.33M
Price to Earnings (P/E)―
Beta2.00
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding420,285,370
10 Day Avg. Volume352,882
30 Day Avg. Volume470,322
Financial Highlights & Ratios
PEG Ratio-0.36
Price to Book (P/B)11.34
Price to Sales (P/S)93.25
P/FCF Ratio-37.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$28.10Price Target Upside-7.63% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
2025 Revenue Ramp & High Gross MarginA clear 2025 revenue inflection with an ~81.5% gross margin indicates the company has product sales that are high-margin at the unit level. If sustained, high gross profitability provides structural leverage to cover fixed R&D and SG&A as volumes scale, aiding path to durable operating profitability once commercial costs stabilize.
Meaningful Equity Base And Moderate LeverageA sizable equity base and low reported leverage provide a structural buffer for an R&D-heavy biotech. This capital structure reduces short-term insolvency risk, supports multi-year development/commercial plans, and gives the company runway to execute clinical/commercial milestones before requiring urgent refinancing.
Narrowing Cash Burn TrendOperating and free cash flow remain negative, but a meaningful reduction in cash burn versus 2023 reflects improving operating leverage or revenue contribution. A sustained narrowing of burn reduces near-term funding needs and increases the likelihood that further scale will convert improved margins into positive free cash flow.
Bears Say
Persistent Large Cash BurnMaterial negative operating and free cash flow across years is a durable risk: ongoing cash burn necessitates external financing, which can dilute shareholders or increase leverage. Continued negative cash generation constrains strategic optionality and increases execution risk for commercial expansion.
Rising Debt In 2025A material increase in debt during 2025 raises refinancing and interest-cost risk if losses persist. Even with current moderate leverage, rising debt combined with negative earnings reduces financial flexibility over time and can pressure credit terms or require equity raises under unfavorable conditions.
Deep Negative Profitability And ReturnsVery large operating losses and deeply negative return metrics signal that the current cost base far outpaces revenue. Structural profitability remains distant without sustained revenue scale or material cost discipline, implying prolonged dilution risk, weak cash conversion, and limited ability to fund growth internally.
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H News
2591 FAQ
What was Guangzhou Innogen Pharmaceutical Group Co Ltd Class H’s price range in the past 12 months?
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H lowest stock price was HK$13.73 and its highest was HK$74.00 in the past 12 months.
What is Guangzhou Innogen Pharmaceutical Group Co Ltd Class H’s market cap?
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H’s market cap is HK$6.40B.
When is Guangzhou Innogen Pharmaceutical Group Co Ltd Class H’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Guangzhou Innogen Pharmaceutical Group Co Ltd Class H’s earnings last quarter?
Currently, no data Available
Is Guangzhou Innogen Pharmaceutical Group Co Ltd Class H overvalued?
According to Wall Street analysts Guangzhou Innogen Pharmaceutical Group Co Ltd Class H’s price is currently Overvalued.
Does Guangzhou Innogen Pharmaceutical Group Co Ltd Class H pay dividends?
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H does not currently pay dividends.
What is Guangzhou Innogen Pharmaceutical Group Co Ltd Class H’s EPS estimate?
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Guangzhou Innogen Pharmaceutical Group Co Ltd Class H have?
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H has 420,285,370 shares outstanding.
What happened to Guangzhou Innogen Pharmaceutical Group Co Ltd Class H’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Guangzhou Innogen Pharmaceutical Group Co Ltd Class H?
Currently, no hedge funds are holding shares in HK:2591
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
-39.43%
Trailing 12-Months
Asset Growth
75.89%
Trailing 12-Months
Company Description
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H
Guangzhou Innogen Pharmaceutl Grp Co Ltd is a China-based investment holding company focused on the research, development, and commercialization of pharmaceutical products, particularly innovative, humanized, long-acting GLP-1 receptor agonists for diabetes and other metabolic diseases
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H (2591) Earnings & Revenues
2591 Stock 12 Month Forecast
Average Price Target
HK$28.10
▼(-7.63% Downside)
Technical Analysis
Alphamab Oncology
―
RemeGen Co. Ltd. Class H
―
Jacobio Pharmaceuticals Group Co., Ltd.
―
CARsgen Therapeutics Holdings Ltd.
―
Ascentage Pharma Group International
―
Options Prices
Currently, No data available
---